This is important because the DUX4 targets that are directly implicated in FSHD pathogenesis are not well-characterized and DUX4-network genes are often used as a biomarker of DUX4 activity, regardless of their physiological role and impact. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.